Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725413 | 0.87 | CA1 (0.33) | CA1CA2CA12CA14 | |
| SCHEMBL15368928 | 0.83 | CA1 (0.35) | CA1CA2CA12CA14 | |
| SCHEMBL13395823 | 0.83 | CA1 (0.35) | CA1CA2CA12CA14 | |
| SCHEMBL8536249 | 0.81 | CA1 (0.48) | CA1CA2CA12CA14CA7 | |
| SCHEMBL9608604 | 0.79 | PTGS1 (0.35) | — | |
| SCHEMBL15368918 | 0.78 | ALDH1A1 (0.42) | CA1CA2CA12CA14CA7 | |
| SCHEMBL1098560 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL10876135 | 0.74 | — | — | |
| SCHEMBL24575966 | 0.73 | FAAH (0.50) | CA2 | |
| SCHEMBL17118120 | 0.73 | FAAH (0.44) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220179141-A1 | OPTICAL FILTER AND IMAGING DEVICE | AGC Inc. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20200354577-A1 | OPTICAL FILTER AND IMAGING DEVICE | AGC Inc. (JP) | 2020-11-12 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20100297553-A1 | POSITIVE RESIST COMPOSITION AND PATTERN-FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | CA1 3329/4885CA2 1724/4885CA12 2958/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885CA12 2755/4885 |
| US-20140155396-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885CA12 2755/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | CA1 3329/4885CA2 1724/4885CA12 2958/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | CA1 3329/4885CA2 1724/4885CA12 2958/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | CA1 967/4885CA2 836/4885CA12 1071/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | CA1 3082/4885CA2 1848/4885CA12 2747/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885CA12 2755/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885CA12 2755/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885CA12 2755/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | CA1 3082/4885CA2 1848/4885CA12 2747/4885 |
| US-20130252940-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885CA12 2755/4885 |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, KDR | CA1 3667/4885CA2 2269/4885CA12 3066/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885CA12 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.